ImmunoGen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMGN research report →
About the company
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer.
- CEO
- Mark Joseph Enyedy
- IPO
- 1989
- Employees
- 277
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $8.73B
- P/E
- -35.54
- P/S
- 80.21
- P/B
- 50.84
- EV/EBITDA
- -39.24
- Div Yield
- 0.00%
- Gross Margin
- 99.84%
- Op Margin
- -203.06%
- Net Margin
- -204.93%
- ROE
- -92.61%
- ROIC
- -95.55%
- Revenue
- $108.78M · 55.72%
- Net Income
- $-222,929,000 · -60.03%
- EPS
- $-0.88 · 18.72%
- Op Income
- $-220,893,000
- FCF YoY
- 0.00%
- 52W High
- $31.25
- 52W Low
- $3.61
- 50D MA
- $29.04
- 200D MA
- $18.87
- Beta
- 1.17
- Avg Volume
- 8.29M
Get TickerSpark's AI analysis on IMGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 12, 24 | MITCHELL DEAN J | sell | 142,667 |
| Feb 12, 24 | MITCHELL DEAN J | sell | 10,000 |
| Feb 12, 24 | MITCHELL DEAN J | sell | 103,000 |
| Feb 12, 24 | MITCHELL DEAN J | sell | 10,000 |
| Feb 12, 24 | MITCHELL DEAN J | sell | 18,000 |
| Feb 12, 24 | MITCHELL DEAN J | sell | 44,000 |
| Feb 12, 24 | MITCHELL DEAN J | sell | 44,000 |
| Feb 12, 24 | MITCHELL DEAN J | sell | 19,597 |
| Feb 12, 24 | MITCHELL DEAN J | sell | 13,090 |
| Feb 12, 24 | Peterson Kristine | sell | 13,090 |
Our IMGN coverage
Recent articles, reports, and earnings notes.
No research on IMGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMGN report →Similar companies
Peers in the same neighborhood.